In the remdesivir study, about 8% of those on the drug died versus 11.6% of the comparison group, but the difference is not large enough for scientists to say the drug was the reason. Separately on Wednesday, California-based Gilead announced partial results from its own ongoing study of the drug in severely ill, hospitalized COVID-19 patients. Yet another study tested remdesivir in severely ill patients in China, which was stopped after only 237 of a planned 453 patients were enrolled. Gilead also is testing remdesivir in a separate study of moderately ill coronavirus patients. Besides these studies, Gilead also has given remdesivir to more than 1,700 patients on a case-by-case emergency basis.

Source: ABC News April 29, 2020 14:26 UTC